FOXP3+ to CD3+ T Cells Ratio Determined by Epigenetic Cell Counting and Cardiovascular Disease Risk
EBioMedicine
Scientific Publications
Peer-reviewed articles and conference poster presentations
All Scientific Literature Publications
-
Download Research Article FOXP3+ to CD3+ T Cells Ratio Determined by Epigenetic Cell Counting and Cardiovascular Disease Risk
-
Download Poster Etrolizumab Treatment Increases Blood Levels of CD3, Treg and Th17 Cells Measured Through Epigenetic Activation of CD3, FOXP3 and IL-17 Loci
Etrolizumab Treatment Increases Blood Levels of CD3, Treg and Th17 Cells Measured Through Epigenetic Activation of CD3, FOXP3 and IL-17 Loci
United European Gastroenterology Week -
Download Research Article Treg-Mediated Immunity & Risk of Solid Cancers: EPIC-Heidelberg Findings
Treg-Mediated Immunity & Risk of Solid Cancers: EPIC-Heidelberg Findings
Journal of the National Cancer Institute -
Download Research Article Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Neuro-Oncology -
Download Research Article In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade
The Journal of Immunology -
Download Research Article Th17/Treg Ratio and Late Phase Asthmatic Response
Th17/Treg Ratio and Late Phase Asthmatic Response
Allergy, Asthma & Clinical Immunology -
Download Research Article ImmunoCRIT: A Definitive Marker for Tumor Aggressiveness & Disease Dissemination
ImmunoCRIT: A Definitive Marker for Tumor Aggressiveness & Disease Dissemination
Epigenetics -
Download Poster Etirinotecan pegol Target-Specific Pharmacodynamic (PD) Biomarkers Measured in Circulating Tumor Cells (CTCs) from Patients in the Phase 3 BEACON Study in Patients with
%20Biomarkers%20Measured%20in%20Circulating%20Tumor%20Cells%20(CTCs)%20from%20Patients%20in%20the%20Phase%203%20BEACON%20Study%20in%20Patients%20with.jpg?width=612&height=283&name=108.%20Etirinotecan%20pegol%20Target-Specific%20Pharmacodynamic%20(PD)%20Biomarkers%20Measured%20in%20Circulating%20Tumor%20Cells%20(CTCs)%20from%20Patients%20in%20the%20Phase%203%20BEACON%20Study%20in%20Patients%20with.jpg)
Etirinotecan pegol Target-Specific Pharmacodynamic (PD) Biomarkers Measured in Circulating Tumor Cells (CTCs) from Patients in the Phase 3 BEACON Study in Patients with
American Society of Clinical Oncology